Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned a consensus rating of "Buy" from the fifteen research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $47.46.

Several research firms recently commented on DYN. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Royal Bank of Canada restated an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. Scotiabank initiated coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company.

Dyne Therapeutics Stock Up 0.9 %

Shares of DYN stock traded up $0.06 on Wednesday, hitting $7.04. The company had a trading volume of 1,349,052 shares, compared to its average volume of 1,473,187. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The firm has a market cap of $796.37 million, a P/E ratio of -1.98 and a beta of 1.21. The company has a 50-day moving average price of $11.86 and a 200-day moving average price of $21.24.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. Equities research analysts expect that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Dyne Therapeutics by 4.2% during the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after buying an additional 5,383 shares during the period. GAMMA Investing LLC raised its position in Dyne Therapeutics by 837.5% in the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after purchasing an additional 2,345 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. Neo Ivy Capital Management purchased a new position in shares of Dyne Therapeutics during the 4th quarter worth $205,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Dyne Therapeutics by 6.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company's stock worth $3,378,000 after purchasing an additional 9,029 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.